期刊
MICROVASCULAR RESEARCH
卷 74, 期 2-3, 页码 85-89出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.mvr.2007.05.005
关键词
ECM; angiogenesis inhibitor; type IV collagen NC1; tumor
资金
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055001, R01DK081576, R01DK062987, R01DK061688] Funding Source: NIH RePORTER
- NIAAA NIH HHS [AA53194] Funding Source: Medline
- NIDDK NIH HHS [DK55001, R01 DK081576, R01 DK061688, R01 DK062987-04, R01 DK061688-03, R01 DK062987, R01 DK055001, R01 DK055001-07S1, DK62987, DK61688] Funding Source: Medline
The concept of anti-angiogenesis therapy was introduced by Judah Folkman in 1971 and since then, a plethora of pro- and anti-angiogenic factors have been identified. In the recent years, it has become clear that angiogenesis, the formation of new capillaries from a pre-existing capillary network, is highly regulated by the action of pro- and anti-angiogenic factors. In the healthy adult organism the angiogenic-switch is likely turned Off, i.e. anti-angiogenic factors are likely counteracting the pro-angiogenic factors resulting in a non-angiogenic state. Angiogenesis is encountered during wound healing processes, the female menstrual cycle and endometrial remodeling, as well as during embryonic development and organ growth. In the pathological setting, angiogenesis plays an important role in different diseases like rheumatoid arthritis, psoriasis, macular degeneration, diabetic retinopathy, and tumor growth. In this regard, recent studies have described several endogenous inhibitors of angiogenesis, with a subset derived from extracellular matrix (ECM) proteins. This review will particularly focus on the type IV collagen-derived angiogenesis inhibitors Arresten, Canstatin and Tumstatin. (C) 2007 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据